Germany’s Merck KGaA suffered a setback in the development of the company’s key cancer immunotherapy Bavencio, which failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.

Biogen Inc. licensed Alkermes Plc’s multiple sclerosis drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug Tecfidera.

Bayer is seeking to defend its pharmaceuticals business that will be diluted in importance by the takeover of Monsanto.

Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to released data.

Acorda Therapeutics Inc. said the company would stop developing its Parkinson’s disease drug tozadenant less than a week after reporting deaths in key studies testing the treatment.

Roche shares were lifted by two clinical trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.

Acorda Therapeutics Inc. said five people died in clinical trials for the company’s Parkinson’s disease drug, the latest in a series of setbacks for the drugmaker.

The U.S. FDA approved Dynavax Technologies’ Heplisav-B as the first new hepatitis B vaccine in the U.S. in more than 25 years.

Swiss drugmaker Roche won a key European panel’s recommendation for its multiple sclerosis drug Ocrevus.

A few months after striking a deal with AbbVie, Bay Area biotech Principia Biopharma signed a deal worth up to $765 million with Sanofi for the development of a multiple sclerosis drug candidate.